BiotechTubeBiotechTube
Home/Pipeline/GT-001 (Gene Therapy)

GT-001 (Gene Therapy)

Parkinson's Disease

Phase 1/2Active

Key Facts

Indication
Parkinson's Disease
Phase
Phase 1/2
Status
Active
Company
Sumitomo Pharma

About Sumitomo Pharma

Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.

View full company profile

Therapeutic Areas

Psychiatry & NeurologyOncologyWomen's HealthRegenerative Medicine

Other Parkinson's Disease Drugs

DrugCompanyPhase
ABBV-951AbbViePhase 3
UCB0107UCBPhase 1
StalevoOrion CorporationApproved
Comtan/ComtessOrion CorporationApproved
CHRONOS-PD PlatformGrifolsResearch
CREXONT (Carbidopa/Levodopa)Amneal PharmaceuticalsApproved
BIIB122/DNL151Denali TherapeuticsPhase 3
ABBV-0805BioArctic ABPhase 1
BAN1202BioArctic ABPreclinical
ARV-102ArvinasPhase 1
AAV-GADMeiraGTxPreclinical/Phase 1
Not SpecifiedMinerva NeurosciencesClinical Stage